The overall age-standardized GD rates increased from 58.2 to 79.3 per 1000 live births between 2016 and 2024, with an average annual percentage change of 3.8% per year.

Lower risk for foot disease driven by lower risk for neuropathy for new users of SGLT-2 inhibitors versus GLP-1 receptor agonists ...

Private equity more likely to enter states with higher autism prevalence and more generous state autism insurance mandates.

Alixorexton is an oral selective orexin 2 receptor agonist expected to reduce excessive daytime sleepiness across hypersomnolence disorders such as narcolepsy.

HealthDay News — Initiation of incretin receptor agonists (IRAs) is associated with lower continuous positive airway pressure (CPAP) use, hospitalization, and mortality among adults with obesity, type ...

Subcutaneous anifrolumab significantly reduces disease activity in patients with moderate to severe systemic lupus erythematosus.

Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.

HealthDay News — Email communications can increase clinician engagement with prescription drug monitoring programs (PDMPs), according to a study published online December 19 in JAMA Health Forum.

At least 7.5 million people had been sickened by late December, resulting in at least 81,000 hospitalizations and 3,100 deaths ...

The sBLA is supported by 1-year interim data from the ongoing phase 4 PETITE-T1D study, which included 23 children less than 8 years of age with stage 2 T1D.

The sNDA for AXS-05 for Alzheimer disease agitation includes findings from four phase 3 trials showing improved behaviors and delayed relapse.

Obexelimab is a monoclonal antibody designed to bind both CD19 and FcγRIIb receptors and inhibit the activity of B-cells linked to autoimmune diseases.